Five-Day vs 10-Day Postexposure Chemoprophylaxis With Oseltamivir to Prevent Hospital Transmission of Influenza: A Noninferiority Randomized Open-Label Study

Lidija Lepen, Rok Blagus, Maša Velušček, Rajko Saletinger, Miroslav Petrovec, Fajko F Bajrović, Daša Stupica, Lidija Lepen, Rok Blagus, Maša Velušček, Rajko Saletinger, Miroslav Petrovec, Fajko F Bajrović, Daša Stupica

Abstract

Background: The efficacy and optimal duration of postexposure influenza prophylaxis with oseltamivir are undetermined in hospital settings, where immediate separation from index cases is not feasible.

Methods: In an open-label noninferiority randomized clinical trial in a single-center university hospital, the efficacy of 5-day vs 10-day postexposure prophylaxis with oseltamivir was compared in adult patients exposed to influenza who could not be immediately separated from index influenza cases. Influenza incidence was assessed for 10 days after discontinuing prophylaxis.

Results: Among 222 exposed patients (median age, 75 years; male 119; median Charlson Comorbidity Index, 5), 110 patients were assigned to 5 days of postexposure prophylaxis with oseltamivir, and 112 patients were assigned to the 10-day group. The median duration of exposure to influenza (interquartile range) was 2 (1-3) days. In the intention-to-treat analysis, the incidence of influenza was 2/110 (1.8%) in the 5-day group and 0/112 (0%) in the 10-day group (difference, 1.8 percentage points; 1-sided 95% CI, -1 to 4.9 percentage points; P = .77).

Conclusions: For patients exposed to influenza in a hospital setting and who were not immediately separated from index cases, postexposure prophylaxis with oseltamivir resulted in low incidence of nosocomial influenza transmission. Five-day postexposure prophylaxis was noninferior to 10-day regimen.

Clinicaltrialsgov registration: NCT03899571.

Keywords: chemoprophylaxis; infection control; influenza; neuraminidase inhibitor.

© The Author(s) 2020. Published by Oxford University Press on behalf of Infectious Diseases Society of America.

Figures

Figure 1.
Figure 1.
Study diagram.

References

    1. Salgado CD, Farr BM, Hall KK, Hayden FG. Influenza in the acute hospital setting. Lancet Infect Dis 2002; 2:145–55.
    1. Sayers G, Igoe D, Carr M, et al. . High morbidity and mortality associated with an outbreak of influenza A(H3N2) in a psycho-geriatric facility. Epidemiol Infect 2013; 141:357–65.
    1. Uyeki TM, Bernstein HH, Bradley JS, et al. . Clinical practice guidelines by the Infectious Diseases Society of America: 2018 update on diagnosis, treatment, chemoprophylaxis, and institutional outbreak management of seasonal influenza. Clin Infect Dis 2019; 68:895–902.
    1. Pop-Vicas A, Rahman M, Gozalo PL, et al. . Estimating the effect of influenza vaccination on nursing home residents’ morbidity and mortality. J Am Geriatr Soc 2015; 63:1798–804.
    1. Okoli GN, Otete HE, Beck CR, Nguyen-Van-Tam JS. Use of neuraminidase inhibitors for rapid containment of influenza: a systematic review and meta-analysis of individual and household transmission studies. PLoS One 2014; 9:e113633.
    1. Centers for Disese Control and Prevention. Influenza antiviral medications: summary for clinicians Available at: . Accessed 19 February 2019.
    1. Centers for Disese Control and Prevention. Prevention strategies for seasonal influenza in healthcare settings. Guidelines and recommendations Available at: . Accessed 19 February 2020.
    1. European Centre for Disease Prevention and Control. Expert opinion on neuraminidase inhibitors for the prevention and treatment of influenza Available at: . Accessed 19 February 2020.
    1. Lau LL, Cowling BJ, Fang VJ, et al. . Viral shedding and clinical illness in naturally acquired influenza virus infections. J Infect Dis 2010; 201:1509–16.
    1. Ip DKM, Lau LLH, Chan KH, et al. . The dynamic relationship between clinical symptomatology and viral shedding in naturally acquired seasonal and pandemic influenza virus infections. Clin Infect Dis 2016; 62:431–7.
    1. Ferguson NM, Cummings DA, Cauchemez S, et al. . Strategies for containing an emerging influenza pandemic in Southeast Asia. Nature 2005; 437:209–14.
    1. Fry AM, Goswami D, Nahar K, et al. . Efficacy of oseltamivir treatment started within 5 days of symptom onset to reduce influenza illness duration and virus shedding in an urban setting in Bangladesh: a randomised placebo-controlled trial. Lancet Infect Dis 2014; 14:109–18.
    1. Hayden FG, Belshe R, Villanueva C, et al. . Management of influenza in households: a prospective, randomized comparison of oseltamivir treatment with or without postexposure prophylaxis. J Infect Dis 2004; 189:440–9.
    1. Higa F, Tateyama M, Tomishima M, et al. . Role of neuraminidase inhibitor chemoprophylaxis in controlling nosocomial influenza: an observational study. Influenza Other Respir Viruses 2012; 6:299–303.
    1. Ishiguro N, Oyamada R, Nasuhara Y, et al. . Three-day regimen of oseltamivir for postexposure prophylaxis of influenza in wards. J Hosp Infect 2016; 94:150–3.
    1. Uršič T, Miksić NG, Lusa L, Strle F, Petrovec M. Viral respiratory infections in a nursing home: a six-month prospective study. BMC Infect Dis 2016; 16:637.
    1. R Development Core Team. R: A Language and Environment for Statistical Computing. Vienna: R Foundation for Statistical Computing; 2016.
    1. Institute of Public Health of the Republic of Slovenia. Ljubljana 2020 Available online: . Accessed 28 April 2020.
    1. Murti M, Whelan M, Friedman L, et al. . Influenza outbreaks in Ontario hospitals 2012–2016. Can Commun Dis Rep 2018; 44:201–5.
    1. Wilson EK, Wood MS, Schaecher EK, et al. . Nosocomial outbreak of influenza A H3N2 in an inpatient oncology unit related to health care workers presenting to work while ill. Am J Infect Control 2019; 7:683–7.
    1. Goodwin K, Viboud C, Simonsen L. Antibody response to influenza vaccination in the elderly: a quantitative review. Vaccine 2006; 24:1159–69.
    1. Gooskens J, Swaan CM, Claas EC, Kroes AC. Rapid molecular detection of influenza outbreaks in nursing homes. J Clin Virol 2008; 41:7–12.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit